Video: Where is the Elaine 2 Study and Just-in-Time Model Right Now? - Halle Moore, MD @HalleMooreMD @CleClinicMD @SWOGOnc #ASCO22 #OncoTwitter

Video: Where is the Elaine 2 Study and Just-in-Time Model...

Annual Meeting Photo
Annual Meeting
3 讞讜讚砖讬诐
119 爪驻讬讜转
专讜爪讛 诇专讗讜转 讗转 讝讛 砖讜讘 诪讗讜讞专 讬讜转专?
讛讬讻谞住 讻讚讬 诇讛讜住讬祝 住专讟讜谉 讝讛 诇驻诇讬讬诇讬住讟. 讛转讞讘专讜转
0 0
拽讟讙讜专讬讛:
转讬讗讜专:

Video: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here

Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract - 聽Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and an ESR1 mutation after progression on prior therapies and Operational metrics for the ELAINE II study combine a traditional approach with a Just-in-Time model.

Brief Overview:

This is an open-label, multicenter, single-arm safety study to assess the safety and tolerability of lasofoxifene and abemaciclib in pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or second lines of hormonal treatment for metastatic disease and have an ESR1 mutation.

馃攰Click to Audio Only